IMW 2021 | Future maintenance therapy approaches for multiple myeloma
Phil McCarthy, MD, of the Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses future approaches to maintenance therapy for multiple myeloma patients, highlighting data from key clinical trials. Dr McCarthy describes the current role of single agent lenalidomide after chemotherapy and stem cell transplantation, and talks on the role of daratumumab-based regimens for patients with relapsed, refractory or transplant ineligible myeloma. Dr McCarthy talks on the Cassiopeia trial (NCT02541383) and the GRIFFIN trial (NCT02874742), which investigated the use of maintenance daratumumab in patients with previously untreated myeloma, and patients with newly diagnosed multiple myeloma, respectively, as well as the PERSEUS trial (NCT03710603). Dr McCarthy also comments on imminent data from the FORTE trial (NCT02203643), which is studying carfilzomib combined with cyclophosphamide-dexamethasone or lenalidomide-dexamethasone in patients with newly diagnosed myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Phil McCarthy, MD, has participated in consultancy work for BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Oncopeptides, Sanofi and Takeda; has received honoraria from BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Medscape, Oncopeptides and Takeda; and has received institutional research grant support from Celgene.
